David Inzunza

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Joseph F. Grosso, Christine E. Horak, David Inzunza et al. · Journal of Clinical Oncology · 2013 · 159 citations

Life Sciences, Immunology, Oncology +17

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

Manish A. Shah, David Cunningham, Jean‐Philippe Metges et al. · Journal for ImmunoTherapy of Cancer · 2021 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Programmed death-ligand 1 (PD-L1) expression in various tumor types

Joseph F. Grosso, David Inzunza, Qiuyan Wu et al. · Journal for ImmunoTherapy of Cancer · 2013 · 28 citations · Full text

Life Sciences, Immunology, Tumor Microenvironment +1

PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA

Dara Burdette, Andrea L. Cathcart, Allyson Shauf et al. · Journal of Hepatology · 2019 · 13 citations

Life Sciences, Infectious Diseases, Molecular Biology +16